morning, Jean-Pierre. you, everyone. Thank Good
with results MORNINGSKY from Slide the begin X, to the Turning I'll Study.
for adolescent pharmacokinetics COVID-XX five placebo-controlled randomized, X:X to randomized recall, safety, will of MORNINGSKY patients or ratio. was the placebo a multi-center, you mild efficacy, either trial, XXX in As milligrams and in moderate twice a with Bemnifosbuvir, days. double-blind, received activity, Phase X Patients antiviral daily and Bemnifosbuvir evaluating adult
previously out we was announced, XXXX, to prior December study As its in the closed completion.
the viral study patients, XX% patient the with size that and a Bemnifosbuvir were study, in hospitalizations and both in enrolled MORNINGSKY the of X, were to comparison were endpoint. treatment risk the achieved we of treatment time FDA, which and arm approximately Study, no The are patients With the already the well risk. difficulty to this being across patients which XX% encouraged a adverse was a of the showed series consistent primary safe represented a secondary In that XX% in XXX X% And to and discontinuation. by baseline. of difference closed and broad are kinetics, MORNINGSKY of geographies, not with finding became alleviation primary variants, the there Bemnifosbuvir the regulatory for deaths the to with patients currently to and with XX% hospitalization, was The age alleviation the endpoint Adverse serious of was no and there to milligrams out vaccinated, high-risk for arm, was comparison study including preferred led generally was populations. sample events events of agencies, Moving no was of across symptoms of seropositive and very Bemnifosbuvir placebo. XX% tolerated. particularly endpoints Slide drug-related to at XXX population who efficacy-evaluable challenging in discontinuation symptoms owing said, The X% placebo. that endpoint which GI-related study the There see BID, events. were were all in a meet, of leading of time lower groups standard are to in symptoms, of the which
Turning chart data deaths. to The the the and illustrates hospitalizations key secondary endpoint in X. Slide of
placebo, the of As I arm, the XX% risk and comparison just value in unadjusted was showed with data equal Bemnifosbuvir in to lower X.XXX a noted, P hospitalization MORNINGSKY with from exploratory.
hospitalization the population the and worth noting because patients. both have It's high-risk especially with in the We’re standard patients. that antivirals of very direct-acting other in a demonstrated in reduction broad encouraged and this consistent the unvaccinated high-risk results were studied, predominantly outcome,
robust. this patients, this in achievement the particularly So, broader of makes efficacy result group
for study double-blind, and Slide were within evaluate randomized BID to now global Patients The were and a of from objectives multi-center daily, five safety, to dose Study Phase efficacy. on results symptom in Phase trial twice antiviral COVID-XX. hospital Bemnifosbuvir XXX patients days placebo-controlled, either to moderate receive high-risk with of patients study the hospitalized or to was onset clinical our The days. such study with tolerability, in Turning assess analysis from setting, was adult ability primary as X on were of placebo inclusion Bemnifosbuvir five or suggests X On for X. randomized, to assess Slide diabetes, the years key patients, XX older, in the endpoint. impact Phase X XX final obesity, progression I’m to hypertension. of an disease The and high-risk overall which risk report our patients age the clinical hospitalized factors rate had study that this benefits. low, potential criteria X, pleased milligrams
event comparison less respiratory of to treatment X.X% and comparison placebo with associated in patients were events, adverse in discontinuation. and events interim previously was reported of in generally no receiving in Bemnifosbuvir, data. in rate Bemnifosbuvir-treated with patients, In overall low, The receiving final this adverse Bemnifosbuvir, deaths was well reported this was serious were arm. three results Notably, Bemnifosbuvir progression deaths to were study, pleased were study, I’m no consistent to with for there the there XX% the the report placebo. progression leading drug-related no the the with those virology with the that severe tolerated, events safe While on in respiratory insufficiency comparison in placebo.
the clinical for Trial of treatment overall hospitalized BID results present milligrams benefits Bemnifosbuvir in COVID-XX. scientific meeting. at Our the planning XXX of an of the study Phase assessment today, reported to the the We're X at and suggests full new data MORNINGSKY upcoming
of demonstrating base which Bemnifosbuvir, remains Turning new against by is the active X, we free variant. data Slide to AT-XXX, were the Omicron very encouraged fully
XXX our size the and conduct that Study study. vitro, longer tolerability As activity the antiviral SARS-CoV-X MORNINGSKY this study the COVID-XX efficacious, to as results BID well potential and data COVID-XX result, the we the to-date, previously next we're outlines favorable against Based We Alpha, Bemnifosbuvir program. profile. previously range a X and reported, patients is monotherapy and in AT-XXX discussed accelerate of of is safe evaluable Slide a program. first believe for steps With in Delta. variants for concern, tolerated, to announced was have has the no Gamma, development X planning the a XX Phase efficacy, that has a is of the in quarter GI potent on And milligrams XXX Phase all inhibitor year. generally Epsilon, of our Bemnifosbuvir including clinical the today, MORNINGSKY outpatient demonstrated
interactions, addition, and there and with no Bemnifosbuvir substrates, drug-drug and co-administration were there there low necessary In non-teratogenic, non-mutagenic, was dose for also CYPXA contraindications. no sero drugs of is risk a are adjustments since that
data pursuing program near-term the for interactions the the to package steps COVID-XX. for and We’re in review clinical in discuss regulatory to next our Bemnifosbuvir
program. now Turning our to fever dengue
is study or baseline. and who multiple within randomized administered change endpoint of a dengue in AT-XXX five AT-XXX, XX days primary in XX Slide placebo from activity, infection a viral fever. noted with study Phase will designed dengue antiviral be of The dengue of X on orally with hours virus up initiated pharmacokinetics fever. present patients patients to in proof-of-concept a for to As with safety, XX, doses of a assess we've load
We this study expect to in later report initial results the from year.
We viral the is volunteers setting, are the allowing dengue then between viral study monitored We and highly Challenge on study, a are treatment Subjects controlled the groups. Study also live United and a administered kinetics dose healthy of dengue quarter results initiated or Slide Human anticipate XX, fourth dosed AT-XXX second this in In closely as in which a of the virus. States. outlined a of within this placebo, with assessment load year.
program. now our Turning to C hepatitis
we to there in standard best-in-class is We our HCV believe opportunity and to As care. Slide with create provides Bemnifosbuvir, combination development the very shown XX, on that plan Ruzasvir, still believe a of HCV the pan-genotypic promising, looks on room combination therapy. current improve
We’re to overview, study for and the but second - year. the the designs, call then that of Andrea? Phase clinical our financial information. half and trial X for assessing starting combination supplies trial as in our - we're I Ruzasvir study, firm and Andrea over the anticipate now Phase trial first currently program, will to hand the expect review With clinical X manufacturing design
